Literature DB >> 3682068

Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule.

M S Anscher1, L R Prosnitz.   

Abstract

Between 1970 and 1983, 442 patients were treated for carcinoma of the prostate at our university medical center. Of the patients 319 underwent radical prostatectomy and 159 (50 per cent) had positive surgical margins and/or seminal vesicle involvement. Of these 159 patients 46 received postoperative irradiation and the actuarial survival was 96, 90 and 90 per cent at 5, 10 and 15 years, respectively. Among the remaining 113 patients who were treated with an operation alone the corresponding figures were 82, 62 and 21 per cent, respectively (p equals 0.02). Considering deaths only of cancer, the surgery only patients had a 15-year actuarial survival of 25 per cent compared to 90 per cent for those who underwent postoperative radiotherapy (p equals 0.07). Actuarial survival free of disease for the surgery plus postoperative irradiation group at 15 years was 40 per cent compared to 28 per cent for the surgery only group (p equals 0.34). Actuarial local control in the irradiated patients was 96 per cent at 15 years versus 32 per cent for the surgery only group (p equals 0.009). Actuarial survival free of distant disease at 15 years was 42 per cent in the irradiated versus 72 per cent in the nonirradiated groups (p equals 0.104). Severe complications attributable to radiation included 3 cases of radiation cystitis, 1 patient with urinary incontinence and leg edema in 9 per cent of the patients undergoing postoperative irradiation compared to 2 per cent of those treated with radical prostatectomy only. Postoperative irradiation appears to be indicated in patients with carcinoma of the prostate who undergo radical prostatectomy and who have positive margins and/or seminal vesicle involvement. Local control is markedly improved (p equals 0.009) and actuarial survival also is benefitted. There was a trend toward decreased deaths of cancer with postoperative irradiation that approached statistical significance. Postoperative irradiation did not improve survival rates free of disease and free of distant disease over those achieved with surgery alone. This finding suggests that while postoperative irradiation may not improve the ultimate cure rate by controlling local disease, early deaths of cancer are reduced resulting in a meaningful increase in survival for these patients.

Entities:  

Mesh:

Year:  1987        PMID: 3682068     DOI: 10.1016/s0022-5347(17)43656-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Radiotherapy: Secondary malignancies after prostate cancer treatment.

Authors:  Judd W Moul
Journal:  Nat Rev Clin Oncol       Date:  2010-05       Impact factor: 66.675

2.  Postoperative radiotherapy in prostate cancer: Analysis of prognostic factors in a series of 282 patients.

Authors:  Giuseppina Apicella; Debora Beldì; Giansilvio Marchioro; Sara Torrente; Sara Tunesi; Corrado Magnani; Alessandro Volpe; Carlo Terrone; Marco Krengli
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-01

3.  Addressing the needs of the high-risk prostate cancer patient.

Authors:  Leonard G Gomella
Journal:  Rev Urol       Date:  2005

4.  Therapeutic strategies for localized prostate cancer I: surgery, ultrasound, adjuvant and neoadjuvant therapy.

Authors:  M I Resnick; E D Crawford; M E Gleave; J Lynch; J P Mulhall; K Pummer; G Vallancien
Journal:  Rev Urol       Date:  2000

5.  A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.

Authors:  Edouard J Trabulsi; Richard K Valicenti; Alexandra L Hanlon; Thomas M Pisansky; Howard M Sandler; Deborah A Kuban; Charles N Catton; Jeff M Michalski; Michael J Zelefsky; Patrick A Kupelian; Daniel W Lin; Mitchell S Anscher; Kevin M Slawin; Claus G Roehrborn; Jeffrey D Forman; Stanley L Liauw; Larry L Kestin; Theodore L DeWeese; Peter T Scardino; Andrew J Stephenson; Alan Pollack
Journal:  Urology       Date:  2008-07-30       Impact factor: 2.649

Review 6.  Coumarin (1,2-benzopyrone) for the treatment of prostatic carcinoma.

Authors:  J L Mohler; B T Williams; I M Thompson; M E Marshall
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 7.  The role of postoperative radiotherapy in prostate cancer patients.

Authors:  Małgorzata Zarzycka; Ewa Ziółkowska; Tomasz Wiśniewski; Wiesława Windorbska; Agnieszka Zyromska; Zbigniew Wolski
Journal:  Contemp Oncol (Pozn)       Date:  2013-10-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.